3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
1
Status
Completed
2
Terminated
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
CNS
3
Sarcoma
1
Conditions
Glioblastoma
3
Lymphoma
2
Sarcoma
1
Recurrence
1
Neoplasms, Plasma Cell
1
Neoplasms, Germ Cell and Embryonal
1
Multiple Myeloma
1
Medulloblastoma
1
Leukemia
1
Gliosarcoma
1
Glioma
1
Carcinoma
1
Astrocytoma
1
Interventions
Temozolomide
107
Radiotherapy
60
Radiation
28
Bevacizumab
19
Magnetic Resonance Spectroscopy
16
Nivolumab
15
Surgical Procedures, Operative
12
Irinotecan
11
Cyclophosphamide
10
Specimen Handling
9
Chemotherapy, Adjuvant
9
Radiotherapy, Intensity-Modulated
8
Radiosurgery
8
O(6)-benzylguanine
8
Carmustine
8
poly ICLC
7
pembrolizumab
7
motexafin gadolinium
7
fludarabine
7
Leukapheresis
7
Flucytosine
7
sargramostim
6
Radiotherapy, Conformal
6
Erlotinib Hydrochloride
6
Lomustine
5
Ipilimumab
5
Imiquimod
5
Imatinib Mesylate
5
Hydroxyurea
5
Granulocyte-Macrophage Colony-Stimulating Factor
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1
×
Glioblastoma
×
Tetanus Toxoid
×
Clear all
NCT00639639
2023-03-13
ATTAC
Duke University
Phase 1
Completed
42 enrolled
NCT02864368
2022-06-09
PERFORMANCE
Duke University
Phase 1
Terminated
27 enrolled
13 charts
NCT03615404
2021-01-28
ATTAC-P
Duke University
Phase 1
Completed
11 enrolled
7 charts